COMMUNIQUÉS West-GlobeNewswire

AC Immune First Half 2026 Financial and Corporate Update
05/08/2026
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, [...]
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
05/08/2026
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
05/08/2026
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
05/08/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]
Verano Announces Strong Second Quarter 2026 Financial Results Highlighted by $218 Million in Revenue
05/08/2026
Company delivers third consecutive quarter of revenue gains and improved cash flow from operations driven by organic growth CHICAGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO [...]
Shopify Delivers Big: 30%+ Growth Across GMV, Revenue, Gross Profit, and Free Cash Flow
05/08/2026
Internet, Everywhere, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Shopify (NASDAQ, TSX: SHOP) announced today financial results for the quarter ended June 30, 2026. Shopify achieved 34% revenue growth (33% in constant currency) [...]
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
05/08/2026
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, [...]
Telix to Host R&D Day in New York City on September 22, 2026
05/08/2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday [...]
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
05/08/2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 [...]
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
05/08/2026
CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Bluesight Launches Revenue Optimization Capabilities, Expanding Margin Insights for Hospital Pharmacies
05/08/2026
Alexandria, Virginia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CostCheck, a drug procurement optimization tool used by more than 500 hospitals, now factors in top-line revenue alongside cost savings to provide pharmacy teams a [...]
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
05/08/2026
Scottish National Investment Bank joins existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company [...]
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 05, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Grace Therapeutics Announces $10 Million Private Placement
05/08/2026
Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “ [...]
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
04/08/2026
New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026
LEXINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
04/08/2026
RESEARCH TRIANGLE PARK, N.C. and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences [...]
Sienna Reports Second Quarter 2026 Financial Results and Forms Redevelopment Joint Venture with Fiera Infrastructure
04/08/2026
MARKHAM, Ontario, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2026. Highlights [...]

Pages